85/100huge gap up break daily accumulation phase
m5 time frame price retest 0.618 fib. level from pre-market
also m5 time frame show selling absorption candle
hope it new up trend
−2.75USD
−161.34 MUSD
1.58 MUSD
52.74 M
About Pliant Therapeutics, Inc.
Sector
Industry
CEO
Bernard Coulie
Website
Headquarters
South San Francisco
Employees (FY)
158
Founded
2015
FIGI
BBG00C8083N4
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
PLRX - Looking for a push off of $18Most recent news from 2 days ago - finance.yahoo.com
Technical look out:
- Looking for MACD to bounce up as it diverges
- RSI cooling off from the overbought zone so we can potentially expect some volume soon
- Price although has shown bear candles on the daily, it has consolidated fairly well con
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PLRX is 12.60 USD — it has increased by 0.64% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pliant Therapeutics, Inc. stocks are traded under the ticker PLRX.
Pliant Therapeutics, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
PLRX stock is 3.52% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is Pliant Therapeutics, Inc. there?
One year price forecast for Pliant Therapeutics, Inc. has a max estimate of 54.00 USD and a min estimate of 33.00 USD.
PLRX earnings for the last quarter are −0.70 USD per share, whereas the estimation was −0.78 USD resulting in a 9.71% surprise. The estimated earnings for the next quarter are −0.81 USD per share. See more details about Pliant Therapeutics, Inc. earnings.
Pliant Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 1.02 M USD. In the next quarter revenue is expected to reach 814.11 K USD.
Yes, you can track Pliant Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
PLRX stock has fallen by 10.95% compared to the previous week, the month change is a 16.50% fall, over the last year Pliant Therapeutics, Inc. has showed a 57.13% decrease.
PLRX net income for the last quarter is −41.11 M USD, while the quarter before that showed −41.49 M USD of net income which accounts for 0.91% change. Track more Pliant Therapeutics, Inc. financial stats to get the full picture.
Today Pliant Therapeutics, Inc. has the market capitalization of 759.01 M, it has decreased by 2.75% over the last week.
No, PLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pliant Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 158.00 employees. See our rating of the largest employees — is Pliant Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pliant Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pliant Therapeutics, Inc. stock shows the sell signal. See more of Pliant Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Pliant Therapeutics, Inc. future price: according to them, PLRX price has a max estimate of 54.00 USD and a min estimate of 33.00 USD. Read a more detailed Pliant Therapeutics, Inc. forecast: see what analysts think of Pliant Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pliant Therapeutics, Inc. EBITDA is −180.47 M USD, and current EBITDA margin is −11.54 K%. See more stats in Pliant Therapeutics, Inc. financial statements.